ADCYAP1 and migraine disorder: More recently, Lu AG09222, a humanized monoclonal antibody directed against the PACAP ligand, successfully inhibited PACAP38-induced cephalic vasodilation while reducing concomitant headache, so is thus a potential therapy against migraine [133].